Hengrui Pharma (Jiangsu Hengrui Pharmaceuticals Co., Ltd.; stock codes: 600276.SH, 01276.HK) is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology.

Hengrui has been ranked on Pharma Exec’s annual list of the top 50 global pharmaceutical companies for seven consecutive years. Furthermore, the company has remained on Citeline’s list of the top 25 global pharma companies by pipeline size for five consecutive years, ranking second globally in the number of independently developed pipeline assets.

Pursuing innovation for health—Hengrui has always prioritized scientific and technological innovation as its primary development strategy and has continued to increase its R&D investment. To date, Hengrui's R&D expenditure has remained above 25% of total revenue for several consecutive years, taking the lead in China's pharmaceutical industry. The company has built a global network of 15 R&D centers across Asia, Europe, the U.S. and Australia, with a worldwide R&D team of over 5,600 professionals. Hengrui’s R&D investment leads to fruitful innovation. The company has commercialized 24 Class 1 innovative drugs and 5 Class 2 innovative drugs in China. Additionally, Hengrui currently has over 100 proprietary innovative candidates in clinical development and is conducting more than 400 clinical trials both domestically and internationally. This has resulted in a robust and sustainable pipeline, featuring a continuous flow of assets that are commercialized, in clinical development, and in early-stage research. In terms of R&D platforms, Hengrui has continuously enhanced its established and mature platforms covering ADCs, bispecific/multi‑specific antibodies, protein degraders, small nucleic acid drugs, oral peptides, and PROTAC/molecular glues/RIPTAC, and has preliminarily built a platform for new molecular modalities. Meanwhile, Hengrui is actively advancing AI‑driven drug discovery (AIDD) to empower innovation in drug R&D.

Bringing Chinese innovative drugs to the world—Globalization is Hengrui's long-term development strategy. At present, the company's pharmaceutical products have reached over 50 countries, and it has obtained approximately 20 overseas regulatory approvals, covering injections, oral formulations and inhalation anesthetics. Furthermore, Hengrui is accelerating its expansion into global markets, with a particular focus on emerging economies. The company places equal emphasis on independent R&D and open cooperation, strengthening international cooperation based on its endogenous development. Since 2023, Hengrui has completed 12 overseas business development transactions with well-known pharmaceutical companies such as MSD and GSK, through various models including out-licensing, NewCo and strategic partnerships. To date, the company has secured the U.S. FDA Fast Track Designation for 4 of its innovative drugs and Orphan Drug Designation for 5 others. Meanwhile, the company has continued to advance its global regulatory efforts, making steady progress in multiple innovative drug regulatory applications in Europe and the U.S.

Moving forward, Hengrui will proceed with the mission of "promoting a healthier life for humankind through advancements in science" and adhere to its vision of "becoming a global biopharmaceutical group through innovation". The company will continue to engage in the innovation and development of treatments for diverse diseases and strive to develop more innovative drugs to benefit patients globally.